\-\ Texto\\:\\ \ \(0\)\
\-\ pt\\ has\\ known\\ rheumatoid\\ arthritis\\.\ \(0\)\
\-\ pharmacologic\\ therapy\\ is\\ the\\ therapeutic\\ mainstay\\ for\\ all\\ patients\\ except\\ those\\ in\\ remission\\.\\ four\\ main\\ classes\\ of\\ drugs\\ are\\ currently\\ used\\:1\\)\\ analgesics\\ \\â\\€\\”\\ drugs\\ that\\ only\\ provide\\ analgesia\\ include\\ acetaminophen\\ \\(eg\\,\\ paracetamol\\)\\,\\ tramadol\\ \\(ultram\\)\\,\\ locally\\ applied\\ capsaicin\\ \\(zostrix\\)\\,\\ and\\ narcotics\\ \\(eg\\,\\ codeine\\)\\;\\ however\\,\\ narcotics\\ should\\ be\\ avoided\\ because\\ of\\ their\\ addictive\\ properties\\.\\ \\ 2\\)\\ nonsteroidal\\ anti\\-inflammatory\\ drugs\\ \\â\\€\\”\\ nsaids\\ have\\ both\\ analgesic\\ and\\ anti\\-inflammatory\\ properties\\ but\\ do\\ not\\ alter\\ disease\\ outcomes\\.\\ \\ agents\\ that\\ block\\ prostaglandin\\ production\\ by\\ selectively\\ inhibiting\\ the\\ cox\\-2\\ isoform\\ appear\\ to\\ share\\ analgesic\\ and\\ antiinflammatory\\ activity\\ with\\ conventional\\ nsaids\\,\\ but\\ exhibit\\ significantly\\ less\\ gastroduodenal\\ toxicity\\.\\ \\ \\ 3\\)\\ glucocorticoids\\ \\â\\€\\”\\ prednisone\\ or\\ prednisolone\\ are\\ most\\ commonly\\ used\\ to\\ suppress\\ inflammation\\,\\ and\\ may\\ be\\ administered\\ orally\\,\\ intravenously\\,\\ or\\ by\\ intraarticular\\ injection\\.\\ \\ 4\\)\\ saards\\ or\\ dmards\\ \\â\\€\\”\\ a\\ miscellaneous\\ group\\ of\\ drugs\\ termed\\ slow\\-acting\\ antirheumatic\\ drugs\\ \\(saards\\)\\ or\\ disease\\-modifying\\ antirheumatic\\ drugs\\ \\(dmards\\)\\ have\\ the\\ potential\\ to\\ reduce\\ or\\ prevent\\ joint\\ damage\\,\\ preserve\\ joint\\ integrity\\ and\\ function\\,\\ reduce\\ health\\ costs\\,\\ and\\ maintain\\ economic\\ productivity\\.\\*\\ such\\ agents\\ include\\ azathioprine\\,\\ cyclosporine\\,\\ d\\-penicillamine\\,\\ gold\\ salts\\,\\ hydroxychloroquine\\,\\ leflunomide\\,\\ methotrexate\\,\\ and\\ sulfasalazine\\.\ \(0\)\
\-\ \\*o\\'dell\\,\\ jr\\.\\ combination\\ dmard\\ therapy\\ for\\ rheumatoid\\ arthritis\\:\\ a\\ step\\ closer\\ to\\ the\\ goal\\.\\ ann\\ rheum\\ dis\\ 1996\\;\\ 55\\:781\\.\ \(0\)\
\-\ pa\\ \\ and\\ lateral\\ radiographs\\ of\\ the\\ hands\\ and\\ wrists\\ show\\ periarticular\\ osteopenia\\.\\ subluxations\\,\\ flexion\\ and\\ extension\\ deformities\\ including\\ boutonniere\\ and\\ swan\\-neck\\ deformities\\,\\ and\\ joint\\ space\\ narrowing\\ are\\ present\\ at\\ the\\ proximal\\ interphalangeal\\ joints\\ and\\ joint\\ space\\ narrowing\\ at\\ the\\ intercarpal\\ joints\\.\\ both\\ first\\ metacarpophalangeal\\ joints\\ are\\ ankylosed\\ with\\ surgical\\ pins\\ traversing\\ these\\ joints\\.\\ \\ joint\\ prostheses\\ are\\ present\\ at\\ the\\ left\\ 2nd\\ and\\ 3rd\\ metacarpo\\-phalangeal\\ joints\\ and\\ the\\ right\\ 2nd\\-5th\\ metacarpophalangeal\\ joints\\.\ \(0\)\
\-\ rheumatoid\\ arthritis\ \(67\)\
\-\ findings\\ consistent\\ with\\ advanced\\ inflammatory\\ arthropathy\\ with\\ post\\-surgical\\ changes\\ and\\ ankyloses\\ as\\ described\\ above\\ \\ and\\ consistent\\ with\\ the\\ patient\\'s\\ known\\ rheumatoid\\ arthritis\\.\ \(0\)\
\-\ 39\\ y\\/o\\ male\\ retired\\ army\\ personnel\\ with\\ known\\ rheumatoid\\ arthritis\\ referred\\ by\\ orthopaedics\\ for\\ routine\\ follow\\-up\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ drugs\\:\\ 0\\.2814217004609435\ \(0\)\
\-\ joints\\:\\ 0\\.24186924342402263\ \(0\)\
\-\ rheumatoid\\:\\ 0\\.20670302900970236\ \(0\)\
\-\ arthritis\\:\\ 0\\.19072570474672026\ \(0\)\
\-\ and\\:\\ 0\\.16475259530907496\ \(0\)\
\-\ joint\\:\\ 0\\.1545237487116533\ \(0\)\
\-\ saards\\:\\ 0\\.15000690404627307\ \(0\)\
\-\ antirheumatic\\:\\ 0\\.15000690404627307\ \(0\)\
\-\ dmards\\:\\ 0\\.14333960510507304\ \(0\)\
\-\ analgesic\\:\\ 0\\.13493980183626925\ \(0\)\
\-\ narcotics\\:\\ 0\\.12354197901347219\ \(0\)\
\-\ properties\\:\\ 0\\.12354197901347219\ \(0\)\
\-\ metacarpophalangeal\\:\\ 0\\.12354197901347219\ \(0\)\
\-\ eg\\:\\ 0\\.09994404827995612\ \(0\)\
\-\ agents\\:\\ 0\\.0980945072841646\ \(0\)\
\-\ reduce\\:\\ 0\\.09550981317945927\ \(0\)\
\-\ deformities\\:\\ 0\\.0952135243983591\ \(0\)\
\-\ inflammatory\\:\\ 0\\.09514031861608954\ \(0\)\
\-\ the\\:\\ 0\\.09358267106450828\ \(0\)\
\-\ nsaids\\:\\ 0\\.09178084740198987\ \(0\)\
\-\ known\\:\\ 0\\.09109351721155041\ \(0\)\
\-\ are\\:\\ 0\\.08898225330667363\ \(0\)\
\-\ 2nd\\:\\ 0\\.08584449468426594\ \(0\)\
\-\ or\\:\\ 0\\.08157852870333275\ \(0\)\
\-\ paracetamol\\:\\ 0\\.07500345202313653\ \(0\)\
\-\ ultram\\:\\ 0\\.07500345202313653\ \(0\)\
\-\ capsaicin\\:\\ 0\\.07500345202313653\ \(0\)\
\-\ zostrix\\:\\ 0\\.07500345202313653\ \(0\)\
\-\ isoform\\:\\ 0\\.07500345202313653\ \(0\)\
\-\ dmard\\:\\ 0\\.07500345202313653\ \(0\)\
\-\ ankylosed\\:\\ 0\\.07500345202313653\ \(0\)\
\-\ narrowing\\:\\ 0\\.07271416753386513\ \(0\)\
\-\ addictive\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ prostaglandin\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ antiinflammatory\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ prednisolone\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ costs\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ productivity\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ salts\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ leflunomide\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ boutonniere\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ personnel\\:\\ 0\\.07166980255253652\ \(0\)\
\-\ used\\:\\ 0\\.07022214428669361\ \(0\)\
\-\ codeine\\:\\ 0\\.069304540611738\ \(0\)\
\-\ inhibiting\\:\\ 0\\.069304540611738\ \(0\)\
\-\ share\\:\\ 0\\.069304540611738\ \(0\)\
\-\ economic\\:\\ 0\\.069304540611738\ \(0\)\
\-\ intercarpal\\:\\ 0\\.069304540611738\ \(0\)\
\-\ selectively\\:\\ 0\\.06746990091813462\ \(0\)\
\-\ intravenously\\:\\ 0\\.06746990091813462\ \(0\)\
\-\ hydroxychloroquine\\:\\ 0\\.06746990091813462\ \(0\)\
\-\ ankyloses\\:\\ 0\\.06746990091813462\ \(0\)\
\-\ miscellaneous\\:\\ 0\\.06597089114113798\ \(0\)\
\-\ sulfasalazine\\:\\ 0\\.06597089114113798\ \(0\)\
\-\ rheum\\:\\ 0\\.06597089114113798\ \(0\)\
\-\ classes\\:\\ 0\\.06470349643337515\ \(0\)\
\-\ tramadol\\:\\ 0\\.06470349643337515\ \(0\)\
\-\ orally\\:\\ 0\\.06470349643337515\ \(0\)\
\-\ pharmacologic\\:\\ 0\\.06360562920033948\ \(0\)\
\-\ nonsteroidal\\:\\ 0\\.06360562920033948\ \(0\)\
\-\ azathioprine\\:\\ 0\\.06360562920033948\ \(0\)\
\-\ cyclosporine\\:\\ 0\\.06360562920033948\ \(0\)\
\-\ subluxations\\:\\ 0\\.06360562920033948\ \(0\)\
\-\ prostheses\\:\\ 0\\.06360562920033948\ \(0\)\
\-\ mainstay\\:\\ 0\\.06263724167053797\ \(0\)\
\-\ pins\\:\\ 0\\.06263724167053797\ \(0\)\
\-\ space\\:\\ 0\\.06243749303295974\ \(0\)\
\-\ analgesia\\:\\ 0\\.061770989506736096\ \(0\)\
\-\ gastroduodenal\\:\\ 0\\.061770989506736096\ \(0\)\
\-\ suppress\\:\\ 0\\.061770989506736096\ \(0\)\
\-\ preserve\\:\\ 0\\.061770989506736096\ \(0\)\
\-\ orthopaedics\\:\\ 0\\.061770989506736096\ \(0\)\
\-\ acetaminophen\\:\\ 0\\.060987369106130083\ \(0\)\
\-\ avoided\\:\\ 0\\.060987369106130083\ \(0\)\
\-\ alter\\:\\ 0\\.060987369106130083\ \(0\)\
\-\ retired\\:\\ 0\\.060987369106130083\ \(0\)\
\-\ ann\\:\\ 0\\.06027197972973945\ \(0\)\
\-\ dis\\:\\ 0\\.06027197972973945\ \(0\)\
\-\ by\\:\\ 0\\.05974949324528126\ \(0\)\
\-\ traversing\\:\\ 0\\.05961388529762843\ \(0\)\
\-\ army\\:\\ 0\\.05961388529762843\ \(0\)\
\-\ glucocorticoids\\:\\ 0\\.05790671778894094\ \(0\)\
\-\ integrity\\:\\ 0\\.057408274804866044\ \(0\)\
\-\ closer\\:\\ 0\\.057408274804866044\ \(0\)\
\-\ remission\\:\\ 0\\.05693833025913943\ \(0\)\
\-\ toxicity\\:\\ 0\\.05693833025913943\ \(0\)\
\-\ intraarticular\\:\\ 0\\.05693833025913943\ \(0\)\
\-\ locally\\:\\ 0\\.05607207809533756\ \(0\)\
\-\ outcomes\\:\\ 0\\.05607207809533756\ \(0\)\
\-\ step\\:\\ 0\\.05607207809533756\ \(0\)\
\-\ interphalangeal\\:\\ 0\\.05607207809533756\ \(0\)\
\-\ include\\:\\ 0\\.05581025155971397\ \(0\)\
\-\ applied\\:\\ 0\\.05528845769473155\ \(0\)\
\-\ periarticular\\:\\ 0\\.05528845769473155\ \(0\)\
\-\ with\\:\\ 0\\.05510174224085836\ \(0\)\
\-\ termed\\:\\ 0\\.054922984582993495\ \(0\)\
\-\ exhibit\\:\\ 0\\.05423743840173418\ \(0\)\
\-\ analgesics\\:\\ 0\\.05391497388622989\ \(0\)\
\-\ jr\\:\\ 0\\.05391497388622989\ \(0\)\
\-\ therapy\\:\\ 0\\.05389428551983523\ \(0\)\
\-\ wrists\\:\\ 0\\.053604680788539416\ \(0\)\
\-\ gold\\:\\ 0\\.053305673610578086\ \(0\)\
\-\ goal\\:\\ 0\\.053305673610578086\ \(0\)\
\-\ at\\:\\ 0\\.053144271733645304\ \(0\)\
\-\ methotrexate\\:\\ 0\\.052738428624737536\ \(0\)\
\-\ block\\:\\ 0\\.0524688375469628\ \(0\)\
\-\ both\\:\\ 0\\.052307586134777276\ \(0\)\
\-\ maintain\\:\\ 0\\.051014150202003755\ \(0\)\
\-\ consistent\\:\\ 0\\.05086060946658669\ \(0\)\
\-\ 1996\\:\\ 0\\.05079488944197909\ \(0\)\
\-\ production\\:\\ 0\\.05037316668393903\ \(0\)\
\-\ prednisone\\:\\ 0\\.04940477915413752\ \(0\)\
\-\ osteopenia\\:\\ 0\\.04870462943221523\ \(0\)\
\-\ administered\\:\\ 0\\.048538526990335645\ \(0\)\
\-\ present\\:\\ 0\\.04813191757523612\ \(0\)\
\-\ conventional\\:\\ 0\\.04790576937714088\ \(0\)\
\-\ therapeutic\\:\\ 0\\.04746123997137908\ \(0\)\
\-\ provide\\:\\ 0\\.04746123997137908\ \(0\)\
\-\ arthropathy\\:\\ 0\\.04746123997137908\ \(0\)\
\-\ to\\:\\ 0\\.04689972020450496\ \(0\)\
\-\ have\\:\\ 0\\.04685833370648853\ \(0\)\
\-\ but\\:\\ 0\\.046384334308048995\ \(0\)\
\-\ health\\:\\ 0\\.046381422781227984\ \(0\)\
\-\ damage\\:\\ 0\\.04565549939797458\ \(0\)\
\-\ surgical\\:\\ 0\\.045589945987740674\ \(0\)\
\-\ group\\:\\ 0\\.04457211990654086\ \(0\)\
\-\ hands\\:\\ 0\\.044471237766857456\ \(0\)\
\-\ significantly\\:\\ 0\\.044079649891295085\ \(0\)\
\-\ advanced\\:\\ 0\\.044079649891295085\ \(0\)\
\-\ except\\:\\ 0\\.04370586774273899\ \(0\)\
\-\ combination\\:\\ 0\\.043525161760196426\ \(0\)\
\-\ prevent\\:\\ 0\\.043005718020816694\ \(0\)\
\-\ 3rd\\:\\ 0\\.04283961557893711\ \(0\)\
\-\ for\\:\\ 0\\.042645170832685535\ \(0\)\
\-\ potential\\:\\ 0\\.04190785078778102\ \(0\)\
\-\ main\\:\\ 0\\.040874468522422984\ \(0\)\
\-\ injection\\:\\ 0\\.04080998355474534\ \(0\)\
\-\ that\\:\\ 0\\.04070575934586479\ \(0\)\
\-\ those\\:\\ 0\\.04013214891811735\ \(0\)\
\-\ flexion\\:\\ 0\\.03984159602494383\ \(0\)\
\-\ disease\\:\\ 0\\.03937398220222641\ \(0\)\
\-\ 39\\:\\ 0\\.03897534386114196\ \(0\)\
\-\ their\\:\\ 0\\.03892411758183356\ \(0\)\
\-\ do\\:\\ 0\\.03887320849514232\ \(0\)\
\-\ described\\:\\ 0\\.03805276030067941\ \(0\)\
\-\ be\\:\\ 0\\.038050982050728495\ \(0\)\
\-\ four\\:\\ 0\\.03800695633134045\ \(0\)\
\-\ function\\:\\ 0\\.037961406124906234\ \(0\)\
\-\ inflammation\\:\\ 0\\.03769328047646105\ \(0\)\
\-\ appear\\:\\ 0\\.03693768666185554\ \(0\)\
\-\ of\\:\\ 0\\.036712559081935575\ \(0\)\
\-\ routine\\:\\ 0\\.0363197966679594\ \(0\)\
\-\ currently\\:\\ 0\\.03602743551027079\ \(0\)\
\-\ pa\\:\\ 0\\.03599161065519451\ \(0\)\
\-\ commonly\\:\\ 0\\.034703814469887365\ \(0\)\
\-\ referred\\:\\ 0\\.034703814469887365\ \(0\)\
\-\ activity\\:\\ 0\\.03443323750671882\ \(0\)\
\-\ above\\:\\ 0\\.03383450644608685\ \(0\)\
\-\ pt\\:\\ 0\\.03375242465387562\ \(0\)\
\-\ including\\:\\ 0\\.033564028395849765\ \(0\)\
\-\ extension\\:\\ 0\\.0331997122237086\ \(0\)\
\-\ because\\:\\ 0\\.032777989465668525\ \(0\)\
\-\ less\\:\\ 0\\.031906902375980956\ \(0\)\
\-\ first\\:\\ 0\\.0316499504878309\ \(0\)\
\-\ should\\:\\ 0\\.030602304929485583\ \(0\)\
\-\ radiographs\\:\\ 0\\.030418775183275598\ \(0\)\
\-\ such\\:\\ 0\\.030168527436752073\ \(0\)\
\-\ show\\:\\ 0\\.029773255504416247\ \(0\)\
\-\ only\\:\\ 0\\.029300514906551934\ \(0\)\
\-\ proximal\\:\\ 0\\.029300514906551934\ \(0\)\
\-\ changes\\:\\ 0\\.028344457864036787\ \(0\)\
\-\ all\\:\\ 0\\.027918505426799422\ \(0\)\
\-\ however\\:\\ 0\\.027759369015643326\ \(0\)\
\-\ these\\:\\ 0\\.02648447267302459\ \(0\)\
\-\ patients\\:\\ 0\\.02638386486280624\ \(0\)\
\-\ most\\:\\ 0\\.02440822636561071\ \(0\)\
\-\ may\\:\\ 0\\.0236016034951534\ \(0\)\
\-\ lateral\\:\\ 0\\.023275484037943363\ \(0\)\
\-\ findings\\:\\ 0\\.02314707495014552\ \(0\)\
\-\ has\\:\\ 0\\.021422593967852437\ \(0\)\
\-\ male\\:\\ 0\\.02088172365879656\ \(0\)\
\-\ as\\:\\ 0\\.01884143013594416\ \(0\)\
\-\ not\\:\\ 0\\.018515039385803223\ \(0\)\
\-\ left\\:\\ 0\\.015998643149416132\ \(0\)\
\-\ right\\:\\ 0\\.015549319937120545\ \(0\)\
\-\ patient\\:\\ 0\\.015254244418982925\ \(0\)\
\-\ is\\:\\ 0\\.012843907932220776\ \(0\)\
\-\ in\\:\\ 0\\.01166721996969776\ \(0\)\
